BeiGene, Ltd. (âBeiGeneâ) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed six drugs and drug candidates, including three marketed drugs in China ABRAXANEÂŽ, REVLIMIDÂŽ and VIDAZAÂŽ under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region. BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of February 27, 2019, the Company had a global team of over 2,200 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization. Source
No articles found.
Together, a potent new drug and a blood test to guide its use can be a life change...
Together, a potent new drug and a blood test to...
We are a network of full-service medical equipment companies that use tailored pro...
We are a network of full-service medical equipm...
China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrat...
China Biologic Products Holdings, Inc. (NASDAQ:...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...
BioDelivery Sciences International, Inc. (NASDA...
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...
Incyte Corporation is a Wilmington, Delaware-ba...
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...
Immunomedics is a clinical-stage biopharmaceuti...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Join the National Investor Network and get the latest information with your interests in mind.